Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00290017 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

400

Enrollment

INDUSTRY

Sponsor class

Stopped FDA Hold May 2007

Conditions

Carcinoma, Non-Small-Cell Lung
Lung Cancer
Neoplasms, Lung
Neoplasms, Pulmonary

Interventions

DRUG: talabostat
DRUG: pemetrexed

Sponsor

Point Therapeutics